Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.

NCT01975376 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01975376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
October 29, 2013
Completion date
March 22, 2017
Enrollment
16,784 (actual)
Sites
1,745

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease